氟桂利嗪联合普奈洛尔治疗偏头痛的观察

目的观察氟桂利嗪联合普奈洛尔治疗无先兆偏头痛的疗效，探讨两药联合应用能否增强疗效。方法146例无先兆偏头痛患者随机分为3组，Ⅰ组50例，氟桂利嗪每晚睡前5mg一次口服，普夸洛尔每次10mg，每日3次口服；Ⅱ组49例，氟桂利嗪每晚睡前5mg一次口服；Ⅲ组47例，普奈洛尔每次10mg，每日3次口服。3组均以90d为疗程，观察3组治疗前后平均每月头痛发作次数、程度的变化及副作用。结果治疗后Ⅰ组总有效率92．0％，Ⅱ组总有效率69．4％，Ⅲ组总有效率63．8％，联合治疗组疗效明显优于单一用药组，v值分别为2．64、3．45，均P〈0．01，3组副作用无明显差异。结论氟桂利嗪与普奈洛尔联合应用能提高治疗无先兆偏头痛的疗效，副作用无增加。     

血府逐瘀口服液联合氟桂利嗪治疗偏头痛临床观察

目的观察血府逐瘀口服液联合氟桂利嗪与单用氟桂利嗪治疗偏头痛的疗效比较。方法将40例临床确诊为偏头痛的患者随机分为两组。血府逐瘀口服液联合氟桂利嗪组(治疗组)21例,单用氟桂利嗪组(对照组)19例,治疗组给予血府逐瘀口服液10 ml口服,3次/d,同时加氟桂利嗪10 mg睡前口服;对照组给予氟桂利嗪10 mg睡前口服。两组均治疗1周为1个疗程。结果治疗组总有效率为95.23%;对照组总有效率为84.21%,两组比较差异有统计学意义(P<0.05);在头痛缓解程度及伴随症状改善上治疗组明显优于对照组。结论血府逐瘀口服液联合氟桂利嗪可明显改善偏头痛患者的头痛发作程度以及伴随症状,疗效确切,值得临床应用。     

正天丸联合氟桂利嗪治疗偏头痛的疗效观察

目的 观察正天丸联合氟桂利嗪治疗偏头痛的临床疗效.方法 将30例偏头痛患者随机分为两组,治疗组和对照组各15例.治疗组采用正天丸联合氟桂利嗪治疗,对照组仅用氟桂利嗪治疗.疗程均为2个月.结果 治疗组总有效率87%,对照组总有效率67%.2组总有效率比较差异具有统计学意义(P＜0.01).结论 正天丸联合氟桂利嗪治疗偏头痛的临床效果好.     

酒石酸美托洛尔联合氟桂利嗪预防性治疗偏头痛的疗效观察

目的探讨酒石酸美托洛尔联合氟桂利嗪预防性治疗偏头痛的疗效。方法将56例偏头痛患者随机分为治疗组与对照组,各28例。治疗组予酒石酸美托洛尔和氟桂利嗪治疗,对照组仅予氟桂利嗪治疗。观察两组疗效。结果治疗组治疗后3、6、9及12个月偏头痛发作频率、发作天数及严重程度均明显减少,与对照组差异均有统计学意义（均〈0.01）。治疗组治疗后3、6、9及12个月治疗总有效率明显优于对照组,差异均有统计学意义（均〈0.01）。结论酒石酸美托洛尔联合氟桂利嗪预防性治疗偏头痛的疗效明显优于单用氟桂利嗪,且不良反应并未增多,值得临床推广应用。     

氟桂利嗪联合乙酰天麻素片治疗女性偏头痛的疗效观察

目的：观察乙酰天麻素片联合盐酸氟桂利嗪胶囊治疗女性偏头痛的疗效及复发率。方法：搜集门诊资料齐全的50例女性偏头痛患者分2组进行观察,联合组为乙酰天麻素片100mgl天3次及氟桂利嗪胶囊10mgl天1次。对照组为氟桂利嗪胶囊10mgl天1次,记录用药头痛缓解程度及4周、8周后头痛的复发率。结果：联合组总有效率96％,对照组总有效率72％。结论：乙酰天麻素片联合盐酸氟桂利嗪胶囊治疗女性偏头痛疗效可靠、稳定,副作用小,复发率低,值得在临床进一步推广应用。     

元神安颗粒联合氟桂利治疗偏头痛50例

目的 观察元神安颗粒联合氟桂利嗪治疗偏头痛的疗效.方法 将96例偏头痛患者随机分为2组,治疗组元神安颗粒加氟桂利嗪,对照组单用氟桂利嗪治疗,10天1疗程,3个疗程后观察疗效.结果 治疗组对偏头痛患者的治愈率和总有效率明显高于对照组,两组有显著差异(P＜0.05).结论 元神安颗粒联合氟桂利嗪治疗偏头痛较单用氟桂利嗪疗效增高.     

盐酸氟桂利嗪联合维脑路通治疗和预防偏头痛106例疗效观察

目的 观察盐酸氟桂利嗪联合维脑路通治疗偏头痛的临床疗效.方法 106例偏头痛患者随机分为2组:治疗组给予盐酸氟桂利嗪5～10 mg,每日睡前口服1次;维脑路通每次200 mg,每日3次口服.对照组给予尼莫地平20 mg,谷维素20 mg,均为每日3次口服.2组均连用30 d.结果 总有效率治疗组为94.6%,对照组为66.0%,2组比较差异有统计学意义(P＜0.05).结论 盐酸氟桂利嗪联合维脑路通治疗偏头痛疗效好,副作用小,值得在临床上推广应用.     

氟桂利嗪联合普萘洛尔治疗偏头痛临床观察

目的:分析氟桂利嗪联合普萘洛尔治疗偏头痛的临床疗效.方法:按照入院顺序奇偶法将我院2015年9月-2017年3月收治的77例偏头痛患者分为治疗组(n=38)和观察组(n=39).观察组采用氟桂利嗪治疗,治疗组采用氟桂利嗪联合普萘洛尔治疗,对比两组患者的临床治疗效果和不良反应发生率.结果:治疗组的好转率为57.89%,康复率为36.84%,总有效率为94.74%,明显优于常规组的好转率48.72%、康复率28.21%以及总有效率76.92%(P<0.05);治疗组的不良反应发生率为2例(5.26%),明显低于观察组7例(17.95%)(P<0.05).结论:氟桂利嗪联合普萘洛尔治疗偏头痛能够明显改善患者的临床症状,提高患者的治疗效果,值得推广.     

养血清脑颗粒联合氟桂利嗪治疗偏头痛的临床观察

目的探讨养血清脑颗粒联合氟桂利嗪治疗偏头痛的临床疗效。方法将62例偏头痛患者随机分为治疗组32例和对照组30例,治疗组用养血清脑颗粒4g/次,3次/d,温水冲服,氟桂利嗪胶囊5~10mg,每日睡前服1次;对照组只服用氟桂利嗪胶囊,剂量同治疗组。2组均连续治疗8周~12周后评定疗效。结果治疗组的总有效率为96.87%,明显高于对照组的76.66%,差异有统计学意义（P〈0.05）。结论养血清脑颗粒是一种有效的治疗偏头痛的药物,联合氟桂利嗪较单用氟桂利嗪疗效明显增高,且无明显毒副作用。     

氟桂利嗪与尼莫地平胶囊预防偏头痛的疗效分析

目的 探讨氟桂利嗪与尼莫地平胶囊预防偏头痛的疗效和安全性,以供临床参考使用.方法 将2009年10月～2011年6月收治的96例偏头痛患者随机分为两组,A实验组患者给予氟桂利嗪治疗,B实验组患者给予尼莫地平治疗,比较两组患者的治疗效果,并将结果进行统计学分析.结果 A实验组患者的总有效率为87.50%(42/48);B实验组患者总有效率为77.08%(37/48),A实验组的总有效率明显优于B实验组,P<0.05.结论 氟桂利嗪与尼莫地平胶囊预防偏头痛均有较好的效果,其中氟桂利嗪的效果更佳.     

Value of D-Dimers in patients with acute aortic dissection

Objective: To evaluatel the value of D-dimers in patients with acute aortic dissection (AAD). Methods: This study consisted of 16 patients with AAD and 27 non-AAD patients. Serum D-dimets were measured by Sta-Liatest D-DI immunoturbidimetric assay. Results: D-dimer level was higher (P ＜ 0.001) in patients with AAD(7.91 ± 5.52 μg/ml) than that in non- AAD group(1.57±1.24 μg/ml). D-dimer was positive (＞0.4 μg/ml) in all patients with AAD and in 10 control group patients (37%). Among patients with acute AAD, D-dimers tended to be higher in Stanford A than in Stanford B (8.67 ± 4.31 μg/ml vs. 3.24±1.27 μg/ml, P ＜0.01). D-dimer values tended to be higher in more extended disease(3.84 ± 1.65 μg/ml, 8.57 ± 3.58 μg/ml and 11.87 ± 5.69 μg/ml in thoracic aorta, thoracic and abdominal aorta, thoracic and abdominal aorta and iliacal arteries, respectively, P ＜ 0.05 for both 8.57 ± 3.58 and 11.87 ± 5.69 vs. 3.84 ± 1.65 ). Including the control group into the analysis, we found a sensitivity of 100%, a negative predictive value of 100%, and a specificity of 66% and a positive predictive value of 64% for D-dimer in diagnosis of AAD in our patients with suspected AAD. Conclusion: D-dimer was elevated in patients with AAD. A negative D-dimer test result could be useful in excluding AAD.     

Research of combined liver-kidney transplantation model in rats

Objective： To set up a simple and reliable rat model of combined liver-kidney transplantation. Methods： SD rats served as both donors and recipients. 4℃ sodium lactate Ringer＇s was infused from portal veins to donated livers,and from abdominal aorta to donated kidneys, respectively. Anastomosis of the portal vein and the inferior vena cava （IVC） inferior to the right kidney between the graft and the recipient was performed by a double cuff method, then the superior hepatic vena cava with suture. A patch of donated renal artery was anastomosed to the recipient abdominal aorta. The urethra and bile duct were reconstructed with a simple inside bracket. Results： Among 65 cases of combined liver-kidney transplantation, the success rate in the late 40 cases was 77.5%. The function of the grafted liver and kidney remained normal. Conclusion： This rat model of combined liver-kidney transplantation can be established in common laboratory conditions with high success rate and meet the needs of renal transplantation experiment.     

BLOOD PRESSURE CHANGE WITH AGE IN SALT-SENSITIVE TEENAGERS

Objective To observe blood pressure change with age in salt-sensitive teenagers whose salt sensitivity were determined by repeated testing.Methods Salt sensitivity was determined through intravenous infusion of normal saline combined with volume-depletion by oral diuretic furosemide in 55 teenagers. After five years, salt sensitivity was re-examined and subject blood pressure was followed up. Blood pressure changes in salt-sensitive teenagers were compared to that of non-salt sensitive teenagers over five years.Results After 5 years, the repetition rate of salt sensitivity determined by intravenous saline loading is 92.7%. In teenagers with salt sensitivity on the baseline, both the systolic blood pressure increments and increment rates were much higher than non-salt sensitive teenagers (12.7±12.1 mmHg vs. 2.8±5.2 mmHg, P＜ 0.01; 12.2%± 12.0% vs. 2.5% ±4.4%, P＜ 0.001,respectively). There was a similar trend for diastolic blood pressure (8.4 ± 6.4 mmHg vs. 3.7 ± 6.4 mmHg, P = 0.052; 13.2% ±10.6 % vs. 6.8%± 10.1%, P = 0.053, respectively).Conclusions Salt sensitivity determined by intravenous saline loading showed good reproducibility. Blood pressure increments with age were much higher in salt-sensitive teenagers than non-salt sensitive teenagers, especially in terms of systolic blood pressure.     

安心颗粒对急诊经皮冠状动脉介入术后生活质量影响的研究

目的：评价使用安心颗粒对急诊经皮冠状动脉介入术（PPCI）术后生活质量的影响.方法：将160例接受PPCI的急性ST段抬高型心肌梗死患者随机分为安心颗粒组（术前顿服安心颗粒8.8g,术后安心颗粒4.4 g/次,每日2次）和对照组（仅接受基础药物治疗）.所有患者均服用阿司匹林、氯吡格雷和阿托伐他汀.分别在入院时、出院前1d、出院后180 d时,应用心肌梗死多维度量表（MIDAS）、中文版SF-36评价量表对患者生活质量评分.并观察术后30 d以内的出血并发症、血小板减少症发生情况.结果：入院时和出院前1d,两组患者的心肌梗死MIDAS、SF-36量表评分比较无差异（P＞0.05）;出院后180 d时,与对照组比较,安心颗粒组MIDAS、SF-36评分明显减低（P＜0.05）;组内与入院时比较,两组出院前1d、出院后180 d时,MIDAS、SF-36评分均降低（P＜0.05）.两组患者在随访期间均无大量出血、少量出血、重度和极重度血小板减少症发生,安心颗粒组有4例、对照组有7例发生不明显出血（P＞0.05）.两组发生轻度血小板减少症的患者数比较无差异（P＞0.05）.结论：PPCI使用安心颗粒,能改善急性ST段抬高型心肌梗死患者的生活质量,且不增加出血风险.     

The comparative studies of the influences of Urapidil and Nicardipine on sino-atrial node function, atrio-ventricular node function and hemodynamics

Objective:To investigate the influences of urapidil and nicardipine on rabbit sinus function,atrio-ventricular node function and hemodynamics.Methods:Thirty-two Angora's rabbits were selected and randomly divided into four groups.U1 group:urapidil 0.25 mg/kg;U2 group:urapidil 0.5 mg/kg;N1 group:nicardipine 10 μg/kg;N2 group:nicardipine 20 μg/kg.All these medicine were administrated within 30 seconds.Measurements were taken before and after the administration of urapidil or nicardipine for the following data:mean blood pressure(MAP),heart rate(HR),sino-atrial conduction time(SACT),maximal sinoatrial recovery time(SNRTmax)corrected sinus node recovery time(CSNRT),index of sinus node recovery time(SNRTI),Wenckebach A-V conduction frequency (WB),and P-R interval.Results:Significant MAP and HR changes were identified in all of the four groups before and after administration of both urapidil and nicardipine.No significant changes could be found in the rest of the parameters.Intergroup analysis showed that SACT and CSNRT of N1 and N2 groups were shorter than those of the U2 group(P＜0.01);the MAP decreased(P＜0.01)and the HR increased drastically(P＜0.01).Conclusions:Neither urapidil(0.25 mg/kg,0.5 mg/kg)nor nicardipine(10μg/kg,20μg/kg)has any significant influence on rabbit sinus function or rabbit atrio-ventricular node function.Nicardipine could be a better choice than urapidil for parafunctional sinus node patients.     

Expression of OPGmRNA and ODFmRNA in the patients of hip fracture due to osteoporosis

Objective：To investigate the gene expression of osteoprotegerin（OPG） and osteoclast differentiation factor（ODF） in the bone tissue of patients with hip fracture due to osteoporosis. Methods：OPGmRNA and ODFmRNA in the bone tissue in 50 cases of osteoporosis sufferers（over 50 years old） with hip fracture（Observer Group） and 30 cases of hip facture sufferers with no osteoporosis（Control group） were analyzed with the Semi-Quantitative RT-PCR method. Results：The mRNA expressed of ODF, OPG were both high in the patients with hip fracture. In the control group, the expression of OPG mRNA was observed, while the expression of ODF mRNA was very slight. Conclusion：Aged patients contained all signals including OPG, ODF that are essential for inducing osteoclastogenesis and promoting bone resorption.     

Dynamic Changes in Serum Estradiol and Progesterone levels in Patients of Premenstrual Syndrome with Adverse Flow of Liver-qi

Objective:To probe into the influence of changes of ovarian hormones on the pathogenesis of the specific sub-type premenstrual syndrome(PMS)and reveal partial microcosmic mechanisms of adverse flow of liver-qi.Methods:Estradiol(E2)and progesterone(P)levels in serum were determined at different phases of menstrual cycle by radioimmunoassay.Results:In the group of PMS with adverse flow of liver-qi.the secretive peak value Of E2 and P at the follicular phase significantly decreased,and the secretive peak value at the luteal phase did not come into being.Conclusions:Low E2 and P secretive peak at the follicular phase and absence of secretive peak at the luteal phase is one of the microcosmic mechanisms of PMS with adverse flow of liver-qi.One of the pathophysiologic mechanisms of specific sub-type PMS is probably the continuous low level of E2and P.     

Real-time Three-dimensional Echocardiography in Assessment of Left Ventricular and Right Ventricular Volumes

Real-time three-dimensional echocardiography (RT3DE)is a new ultrasound technique that enables dynamic threedimensional visualization and quantification of the heart in real time. Investigation of feasibility and methodology of RT3DE in determining left ventricular (LV) and right ventricular (RV) volumes, RT3DE was performed in 35 normal adults using Philips SONOS 7500 system with a 2-4 MHz matrix array transducer. The 60°×60° "pyramid" volume database was obtained and analyzed on a TomTec echo workstation. Both LV and RV volumes were calculated with four 3DE methods (i.e. apical 2, 4, 8, and 16-plane) through manually tracing ventricular endocardial borders in end diastole and end systole. Stroke volumes were then calculated. LV volume was also measured by 2DE Simpson's rule using GE VIVID 7 ultrasound machine.     

SCREENING FOR A 21-CHROMOSOME ABNORMALITY IN PREIMPLANTED EMBRYOS OF ELDERLY WOMEN

Increasing maternal age is the only etiological factor unequivocally linked to Down's syndrome in humans. The occurrence rate of newborns with Down's syndrome is about 1/220 in women over 35 years old. However, the occurrence rate in embryos fertilized in vitro, of the elder woman is unclear. Using FISH we screened the number of chromosome 21 in preimplanted embryos of 5 elderly women (average age, 38.4 years) to study the feasibility and necessity of screening trisomy 21 in embryos in patients over 35 years old at the in vitro fertilization (IVF) center.     

Scientific principles and rigorous processes should be followed in developing clinical guidelines for therapeutic interventions of integrative medicine

A clinical guideline for the therapeutic interventions of integrative medicine may be defined as a written document which states a series of recommendations on therapeutic interventions of integrative medicine for a special disease or condition. The guideline may provide assistance to medical professionals in making clinical decisions aimed at improving the clinical outcome of patients and reducing the costs of medical care（~＇4~. Recommendations issued by a guideline should be based on the best available evidence in both Western and Chinese medicine. For fulfilling this purpose, the development of clinical guidelines for therapeutic interventions in the field of integrative medicine should follow scientific principles and undergo a rigorous processes.